{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:46:12Z","timestamp":1789908372275,"version":"4.0.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"name":"Agence Nationale de Recherches sur le SIDA et les H\u00e9patites virales"},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1093\/jac\/dky198","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T11:08:54Z","timestamp":1525259334000},"page":"2485-2492","source":"Crossref","is-referenced-by-count":25,"title":["Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing"],"prefix":"10.1093","volume":"73","author":[{"given":"T","family":"Nguyen","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D B","family":"Fofana","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Saint-Antoine, Laboratoire de virologie, F-75012 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M P","family":"L\u00ea","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, D\u00e9partement de Pharmaco-Toxicologie, H\u00f4pital Bichat-Claude Bernard, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Charpentier","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat-Claude Bernard, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Peytavin","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, D\u00e9partement de Pharmaco-Toxicologie, H\u00f4pital Bichat-Claude Bernard, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Wirden","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lambert-Niclot","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Saint-Antoine, Laboratoire de virologie, F-75012 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Desire","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Grude","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Morand-Joubert","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Saint-Antoine, Laboratoire de virologie, F-75012 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-3522","authenticated-orcid":false,"given":"P","family":"Flandre","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Katlama","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service de maladies infectieuses, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Descamps","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat-Claude Bernard, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Todesco","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A G","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,4]]},"reference":[{"key":"key\n\t\t\t\t20180823025401_dky198-B1","author":"Conseil national du sida et des h\u00e9patites virales","year":"2017"},{"key":"key\n\t\t\t\t20180823025401_dky198-B2","author":"US Department of Health and Human Services","year":"2016"},{"key":"key\n\t\t\t\t20180823025401_dky198-B3","author":"European AIDS Clinical Society","year":"2017"},{"key":"key\n\t\t\t\t20180823025401_dky198-B4","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180823025401_dky198-B5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijantimicag.2013.02.016","article-title":"A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure","volume":"42","author":"Marcelin","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180823025401_dky198-B6","doi-asserted-by":"crossref","first-page":"e52562.","DOI":"10.1371\/journal.pone.0052562","article-title":"Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180823025401_dky198-B7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/QCO.0b013e32835a1de7","article-title":"Emerging patterns and implications of HIV-1 integrase inhibitor resistance","volume":"25","author":"Geretti","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"key\n\t\t\t\t20180823025401_dky198-B8","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.02568-12","article-title":"Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness","volume":"57","author":"Abram","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B9","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/infdis\/jir636","article-title":"Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S\/GSK1349572) using clonal viral variants selected in patients failing raltegravir","volume":"204","author":"Canducci","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180823025401_dky198-B10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/AAC.01733-09","article-title":"Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates","volume":"55","author":"Van Wesenbeeck","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/aid.2010.0370","article-title":"Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations","volume":"28","author":"Garrido","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180823025401_dky198-B13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/jac\/dku535","article-title":"Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients","volume":"70","author":"Fourati","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B14","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.3390\/v6093377","article-title":"Is resistance to dolutegravir possible when this drug is used in first-line therapy?","volume":"6","author":"Mespl\u00e8de","year":"2014","journal-title":"Viruses"},{"key":"key\n\t\t\t\t20180823025401_dky198-B15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3851\/IMP3082","article-title":"Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results","volume":"22","author":"Oldenbuettel","year":"2017","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180823025401_dky198-B16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jac\/dku426","article-title":"Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing","volume":"70","author":"Cozzi-Lepri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/infdis\/jis925","article-title":"Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure","volume":"207","author":"Li","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180823025401_dky198-B18","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/jac\/dkv048","article-title":"Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response","volume":"70","author":"Charpentier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B19","doi-asserted-by":"crossref","first-page":"e30118.","DOI":"10.1371\/journal.pone.0030118","article-title":"Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing","volume":"7","author":"Lataillade","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180823025401_dky198-B20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jac\/dkx366","article-title":"No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir","volume":"73","author":"Perrier","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B21","doi-asserted-by":"crossref","first-page":"e90485.","DOI":"10.1371\/journal.pone.0090485","article-title":"Comparison of Illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180823025401_dky198-B22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jir821","article-title":"Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing","volume":"205","author":"Armenia","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180823025401_dky198-B23","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"key\n\t\t\t\t20180823025401_dky198-B24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":"Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals","volume":"43","author":"Markowitz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180823025401_dky198-B25","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jac\/dkv425","article-title":"Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake","volume":"71","author":"Elliot","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B26","author":"Song"},{"key":"key\n\t\t\t\t20180823025401_dky198-B27","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00922-17","article-title":"Mutations located outside the integrase gene can confer resistance to HIV-1 integrase strand transfer inhibitors","volume":"8","author":"Malet","year":"2017","journal-title":"MBio"},{"key":"key\n\t\t\t\t20180823025401_dky198-B28","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1128\/AAC.04844-14","article-title":"Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro","volume":"59","author":"Seki","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.antiviral.2011.12.008","article-title":"In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4","volume":"93","author":"Margot","year":"2012","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180823025401_dky198-B30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jcv.2015.11.009","article-title":"Identification of minority resistance mutations in the HIV-1 integrase coding region using next generation sequencing","volume":"73","author":"Fonager","year":"2015","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20180823025401_dky198-B31","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/QAD.0000000000000267","article-title":"Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure","volume":"28","author":"Mohamed","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180823025401_dky198-B32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.antiviral.2010.09.016","article-title":"Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure","volume":"88","author":"Codo\u00f1er","year":"2010","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180823025401_dky198-B33","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1128\/AAC.01492-10","article-title":"Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment","volume":"55","author":"Liu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B34","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir\u2009+\u2009lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180823025401_dky198-B35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.virusres.2016.12.009","article-title":"Error rates, PCR recombination, and sampling depth in HIV-1 whole genome deep sequencing","volume":"239","author":"Zanini","year":"2017","journal-title":"Virus Res"},{"key":"key\n\t\t\t\t20180823025401_dky198-B36","doi-asserted-by":"crossref","first-page":"42215.","DOI":"10.1038\/srep42215","article-title":"Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use","volume":"7","author":"Raymond","year":"2017","journal-title":"Sci Rep"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/9\/2485\/25523249\/dky198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T15:09:57Z","timestamp":1661094597000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/9\/2485\/5032787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,4]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,6,4]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky198","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2018,6,4]]}}}